Cited by 76Pancreatic and Hepatic Oncology ResearchCancer Cells and MetastasisPancreatic function and diabetes

In vivo reprogramming drives Kras-induced cancer development

Open access
Shibata, Hirofumi, Komura, Shingo, Yamada, Yosuke, Sankoda, Nao, Tanaka, Akito, Ukai, Tomoyo, Kabata, Mio, Sakurai, Satoko +7 more·2018·Nature Communications

Abstract

The faithful shutdown of the somatic program occurs in the early stage of reprogramming. Here, we examined the effect of in vivo reprogramming on Kras-induced cancer development. We show that the transient expression of reprogramming factors (1–3 days) in pancreatic acinar cells results in the transient repression of acinar cell enhancers, which are similarly observed in pancreatitis. We next demonstrate that Kras and p53 mutations are insufficient to induce ERK signaling in the pancreas. Notably, the transient expression of reprogramming factors in Kras mutant mice is sufficient to induce the robust and persistent activation of ERK signaling in acinar cells and rapid formation of pancreatic ductal adenocarcinoma. In contrast, the forced expression of acinar cell-related transcription factors inhibits the pancreatitis-induced activation of ERK signaling and development of precancerous lesions in Kras-mutated acinar cells. These results underscore a crucial role of dedifferentiation-associated epigenetic regulations in the initiation of pancreatic cancers.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1038/s41467-018-04449-5

Cites

72 of 72 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cites

Flagged first, then by citations

Cited by

Sorted by citations

Authors
Shibata, H., Komura, S., Yamada, Y., Sankoda, N., Tanaka, A., Ukai, T., Kabata, M., Sakurai, S., Kuze, B., Woltjen, K., Haga, H., Ito, Y., Kawaguchi, Y., Yamamoto, T., & Yamada, Y.
Affiliations
  • Kyoto University (JP)
  • Gifu University (JP)
  • Kyoto University Hospital (JP)
Corresponding author
Yamada, Yasuhiro
Venue
Nature Communications
Published
2018-05-25
Volume
9
Issue
1
Pages
2081-2081
ISSN
2041-1723 (ISSN-L)
OpenAlex
W2803200695
Cited by
76
References
71
Citations by year
2026: 6 · 2025: 10 · 2024: 8 · 2023: 9 · 2022: 15 · 2021: 12 · 2020: 6 · 2019: 8 · 2018: 2
FWCI
2.63
Type
journal article
Language
en
Open access
Locations
  • Nature Communications (publishedVersion, cc-by)
  • Europe PMC (PubMed Central) (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • Institutional Repositories DataBase (IRDB) (submittedVersion, cc-by)
  • RePEc: Research Papers in Economics (submittedVersion)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
  • Kyoto University Research Information Repository (Kyoto University) (submittedVersion, cc-by)
Funders
  • Naito Foundation
  • Takeda Science Foundation
  • Japan Agency for Medical Research and Development (CREST, JP18gm1110004, JP18cm0106203, 17jm0210039h0005)
  • Research Center Network for Realization of Regenerative Medicine
  • Princess Takamatsu Cancer Research Fund
  • Japan Society for the Promotion of Science (15H04721, CREST, 19K21352, 16H06276, 18H04026)
  • Core Research for Evolutional Science and Technology (JP18gm1110004)
  • Strategic International Collaborative Research Program
Topics
  • Health Sciences › Medicine › Oncology › Pancreatic and Hepatic Oncology Research
  • Health Sciences › Medicine › Oncology › Cancer Cells and Metastasis
  • Health Sciences › Medicine › Surgery › Pancreatic function and diabetes
Keywords
in vivo reprogramming, pancreatic ductal adenocarcinoma, ERK signaling, pancreatic acinar cells, dedifferentiation, epigenetic regulation, p53, pancreatitis, precancerous lesions, transcription factors, tumor initiation
MeSH terms
Mouse Embryonic Stem Cells, alpha-Fetoproteins, Animals, Cell Transformation, Neoplastic, Female, Humans, Male, Mice, Inbred C57BL, Mice, Inbred ICR, Mice, Transgenic, Mutation, Pancreas, Pancreatic Neoplasms, Stomach, Stomach Neoplasms, Transcription Factors, Gene Expression Regulation, Neoplastic, Proto-Oncogene Proteins p21(ras), MAP Kinase Signaling System, Carcinoma, Pancreatic Ductal, Epigenesis, Genetic, Mice, Acinar Cells, Cellular Reprogramming

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review